Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Epistemonikos ID: 3a901177b274c3864c8f8bf754f4d5a88ad8596c
First added on: Aug 01, 2024